Monopar Therapeutics reported a net loss of $5.3 million, or $0.62 per share, for Q2 2026, significantly better than the consensus estimate of $0.85. With shares up 67.5% year-to-date, the results reflect potential investor confidence amid promising developments for ALXN1840.
Key Highlights
- Monopar's shares are up 67.5% year-to-date.
- Short interest decreased to 16% of shares outstanding, down 22%.
- Monopar Therapeutics (NASDAQ: MNPR) faced a net loss of $5.3 million for the second quarter of 2026, translating to $0.62 per share.
Monopar Therapeutics (NASDAQ: MNPR) faced a net loss of $5.3 million for the second quarter of 2026, translating to $0.62 per share. This ongoing financial recovery highlights the company's increasing stability amidst ongoing developments in its drug pipeline, particularly for ALXN1840, which is progressing toward regulatory review. Year-to-date, MNPR shares have surged 67.5%, underscoring growing investor interest and confidence as the company evolves in the biopharmaceutical sector.
Financial Position Snapshot
As of June 30, 2026, Monopar reported cash, cash equivalents, and investments totaling $134.3 million. The latest funding is expected to sustain operations well into 2027, supporting critical processes like regulatory activities for ALXN1840 and ongoing research projects. Monopar’s increase in net loss reflects higher Research and Development expenditures that rose from $1.7 million in the same quarter a year prior to approximately $4.77 million this quarter.
This Investment trajectory signals the company’s commitment to advancing its therapeutic programs, which may ultimately bolster its long-term Market Value despite current losses.
Market Response and Comparison
Monopar’s stock performance has been notably buoyant, with shares up 7.0% in the last month and maintaining a market cap of approximately $779 million. This comes amid broader market trends, with sector peers like FTH up 1.9% and CADL up 1.1% on the same day. As of July 31, the short Interest Rate stands at 16%, decreasing by 22% from the prior settlement, which could indicate shifting sentiment toward a more positive outlook among investors.
The current 52-week trading range for MNPR shares is between $29.18 and $124.82, further reflecting its volatile yet promising position as it navigates the drug approval environment.
Regulatory Progress of ALXN1840
Recent developments regarding ALXN1840, targeted at treating Wilson disease, mark a significant milestone for Monopar. On July 22, the company commenced a rolling New Drug Application (NDA) submission to the FDA, following the recent Rare Pediatric Disease designation. This approval not only positions Monopar favorably for potential Marketing incentives but also enhances its strategic readiness for a commercial launch led by newly appointed Chief Commercial Officer Susan Rodriguez.
Following substantial clinical trial results indicating significant neurologic improvements with ALXN1840, investors are keenly anticipating updates on the NDA submission, expected within the next few months.
Peers Moving on This News
- Faeth Therapeutics, Inc (NASDAQ: FTH) up 1.9%
- Rigel Pharmaceuticals Inc (NASDAQ: RIGL) up 1.2%
- Candel Therapeutics Inc (NASDAQ: CADL) up 1.1%






Please wait processing your request...